AURX (Nuo Therapeutics) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 06, 2026)


AURX Nuo Therapeutics Inc AURX
33 GF Score
Price $1.01
GF Value $4.27
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nuo Therapeutics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Nuo Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

AURX vs PDSB, LTRN, VERU: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Nuo Therapeutics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuo Therapeutics Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's Margin of Safety % (DCF Dividends Based) falls into.


AURX
33GF Score
Nuo Therapeutics Inc AURX
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nuo Therapeutics (AURX) Overvalued in 2026?

Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued. The current stock price of $1.01 is trading 76.3% below its estimated GF Value™ of $4.27. GuruFocus considers Nuo Therapeutics to be Possible Value Trap.

Key valuation signals for AURX:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $4.27 vs. price of $1.01 (76.3% below fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nuo Therapeutics Business Description

Address 8285 El Rio Street, Suite 190, Houston, TX, USA, 77054
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score

Get the complete analysis for AURX

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.01
Price
$4.27
GF Value